Broad neutralization of calcium-permeable amyloid pore channels with a chimeric Alzheimer/Parkinson peptide targeting brain gangliosides

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1862, Issue 2, 2016, Pages 213-222

  Di Scala, Coralie ^a   Yahi, Nouara ^a   Flores, Alessandra ^a   Boutemeur, Sonia ^a   Kourdougli, Nazim ^b   Chahinian, Henri ^a   Fantini, Jacques ^a  

^a Aix Marseille University   (France)

^b Turing Center for Living Systems CENTURI Aix Marseille University   (France)

Author keywords

Alzheimer; Amyloid pore; Calcium; Ganglioside; Ion channel; Parkinson; Synuclein; amyloid peptide

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; CALCIUM ION; CHIMERIC PROTEIN; GANGLIOSIDE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CHANNEL GATING; CONTROLLED STUDY; ELECTROENCEPHALOGRAM; ELECTROPHYSIOLOGICAL PROCEDURES; FLUORESCENCE MICROSCOPY; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HIPPOCAMPAL SLICE; IMMUNOCYTOCHEMISTRY; MOLECULAR DYNAMICS; NERVE CELL; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TARGETING; RAT; SYNAPSE VESICLE;

EID: 84949487128     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.11.012     Document Type: Article

References (82)

1. Recchia A., Debetto P., Negro A., Guidolin D., Skaper S.D., Giusti P. Alpha-synuclein and Parkinson's disease. FASEB J. 2004, 18:617-626.
2. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
3. Jang H., Connelly L., Arce F.T., Ramachandran S., Lal R., Kagan B.L., Nussinov R. Alzheimer's disease: which type of amyloid-preventing drug agents to employ?. Phys. Chem. Chem. Phys. 2013, 15:8868-8877.
4. Aguzzi A., O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat. Rev. Drug Discov. 2010, 9:237-248.
5. Greenwald J., Riek R. Biology of amyloid: structure, function, and regulation. Structure 2010, 18:1244-1260.
6. Buxbaum J.N., Linke R.P. A molecular history of the amyloidoses. J. Mol. Biol. 2012, 421:142-159.
7. Bolshette N.B., Thakur K.K., Bidkar A.P., Trandafir C., Kumar P., Gogoi R. Protein folding and misfolding in the neurodegenerative disorders: a review. Rev. Neurol. 2014, 170:151-161.
8. Parihar M.S., Hemnani T. Alzheimer's disease pathogenesis and therapeutic interventions. J. Clin. Neurosci. 2004, 11:456-467.
9. Golde T.E. Open questions for Alzheimer's disease immunotherapy. Alzheimers Res. Ther. 2014, 6:3.
10. Rosenblum W.I. Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult. Neurobiol. Aging 2014, 35:969-974.
11. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
12. Esparza T.J., Zhao H., Cirrito J.R., Cairns N.J., Bateman R.J., Holtzman D.M., Brody D.L. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann. Neurol. 2013, 73:104-119.
13. Snowdon D.A. Aging and Alzheimer's disease: lessons from the Nun Study. The Gerontologist 1997, 37:150-156.
14. Glabe C.G. Structural classification of toxic amyloid oligomers. J. Biolumin. Chemilumin. 2008, 283:29639-29643.
15. Mucke L., Selkoe D.J. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2012, 2:a006338.
16. Walsh D.M., Selkoe D.J. A beta oligomers - a decade of discovery. J. Neurochem. 2007, 101:1172-1184.
17. Lasagna-Reeves C.A., Glabe C.G., Kayed R. Amyloid-beta annular protofibrils evade fibrillar fate in Alzheimer disease brain. J. Biolumin. Chemilumin. 2011, 286:22122-22130.
18. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
19. Kawahara M., Arispe N., Kuroda Y., Rojas E. Alzheimer's disease amyloid beta-protein forms Zn(2+)-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons. Biophys. J. 1997, 73:67-75.
20. Quist A., Doudevski I., Lin H., Azimova R., Ng D., Frangione B., Kagan B., Ghiso J., Lal R. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:10427-10432.
21. Lal R., Lin H., Quist A.P. Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm. Biochim. Biophys. Acta 2007, 1768:1966-1975.
22. Di Scala C., Chahinian H., Yahi N., Garmy N., Fantini J. Interaction of Alzheimer's beta-amyloid peptides with cholesterol: mechanistic insights into amyloid pore formation. Biochemistry 2014, 53:4489-4502.
23. Kawahara M. Disruption of calcium homeostasis in the pathogenesis of Alzheimer's disease and other conformational diseases. Curr. Alzheimer Res. 2004, 1:87-95.
24. Pollard H.B., Rojas E., Arispe N. A new hypothesis for the mechanism of amyloid toxicity, based on the calcium channel activity of amyloid beta protein (A beta P) in phospholipid bilayer membranes. Ann. N. Y. Acad. Sci. 1993, 695:165-168.
25. Fantini J., Di Scala C., Yahi N., Troadec J.D., Sadelli K., Chahinian H., Garmy N. Bexarotene blocks calcium-permeable ion channels formed by neurotoxic Alzheimer's ss-amyloid peptides. ACS Chem. Neurosci. 2014, 53:216-224.
26. Yanagisawa K. Pathological significance of ganglioside clusters in Alzheimer's disease. J. Neurochem. 2011, 116:806-812.
27. Fantini J., Yahi N. Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: common mechanisms in neurodegenerative diseases. Expert Rev. Mol. Med. 2010, 12:e27.
28. Ikeda K., Matsuzaki K. Driving force of binding of amyloid beta-protein to lipid bilayers. Biochem. Biophys. Res. Commun. 2008, 370:525-529.
29. Hong S., Ostaszewski B.L., Yang T., O'Malley T.T., Jin M., Yanagisawa K., Li S., Bartels T., Selkoe D.J. Soluble Abeta oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron 2014, 82:308-319.
30. Ariga T., Kobayashi K., Hasegawa A., Kiso M., Ishida H., Miyatake T. Characterization of high-affinity binding between gangliosides and amyloid beta-protein. Arch. Biochem. Biophys. 2001, 388:225-230.
31. Utsumi M., Yamaguchi Y., Sasakawa H., Yamamoto N., Yanagisawa K., Kato K. Up-and-down topological mode of amyloid beta-peptide lying on hydrophilic/hydrophobic interface of ganglioside clusters. Glycoconj. J. 2009, 26:999-1006.
32. Yahi N., Aulas A., Fantini J. How cholesterol constrains glycolipid conformation for optimal recognition of Alzheimer's beta amyloid peptide (Abeta1-40). PLoS One 2010, 5:e9079.
33. Hoshino T., Mahmood M.I., Mori K., Matsuzaki K. Binding and aggregation mechanism of amyloid beta-peptides onto the GM1 ganglioside-containing lipid membrane. J. Phys. Chem. B 2013, 117:8085-8094.
34. Ueno H., Yamaguchi T., Fukunaga S., Okada Y., Yano Y., Hoshino M., Matsuzaki K. Comparison between the aggregation of human and rodent amyloid beta-proteins in GM1 ganglioside clusters. Biochemistry 2014, 53:7523-7530.
35. Martinez Z., Zhu M., Han S., Fink A.L. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry 2007, 46:1868-1877.
36. Fantini J., Yahi N. Molecular basis for the glycosphingolipid-binding specificity of alpha-synuclein: key role of tyrosine 39 in membrane insertion. J. Mol. Biol. 2011, 408:654-669.
37. Yamaguchi T., Uno T., Uekusa Y., Yagi-Utsumi M., Kato K. Ganglioside-embedding small bicelles for probing membrane-landing processes of intrinsically disordered proteins. Chem. Commun. (Camb.) 2013, 49:1235-1237.
38. Fantini J., Yahi N. Brain lipids in synaptic function and neurological disease. Clues to Innovative Therapeutic Strategies for Brain Disorders 2015, Elsevier Academic Press, San Francisco.
39. Sanghera N., Correia B.E., Correia J.R., Ludwig C., Agarwal S., Nakamura H.K., Kuwata K., Samain E., Gill A.C., Bonev B.B., Pinheiro T.J. Deciphering the molecular details for the binding of the prion protein to main ganglioside GM1 of neuronal membranes. Chem. Biol. 2011, 18:1422-1431.
40. Yahi N., Fantini J. Deciphering the glycolipid code of Alzheimer's and Parkinson's amyloid proteins allowed the creation of a universal ganglioside-binding Peptide. PLoS One 2014, 9:e104751.
41. Arispe N., Pollard H.B., Rojas E. Zn2+ interaction with Alzheimer amyloid beta protein calcium channels. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:1710-1715.
42. Rhee S.K., Quist A.P., Lal R. Amyloid beta protein-(1-42) forms calcium-permeable, Zn2+-sensitive channel. J. Biolumin. Chemilumin. 1998, 273:13379-13382.
43. Puri A., Rawat S.S., Lin H.M., Finnegan C.M., Mikovits J., Ruscetti F.W., Blumenthal R. An inhibitor of glycosphingolipid metabolism blocks HIV-1 infection of primary T-cells. AIDS 2004, 18:849-858.
44. Fantini J., Tamalet C., Hammache D., Tourres C., Duclos N., Yahi N. HIV-1-induced perturbations of glycosphingolipid metabolism are cell-specific and can be detected at early stages of HIV-1 infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1998, 19:221-229.
45. Abe A. Modification of the Coomassie brilliant blue staining method for sphingolipids and sphingolipid synthesis inhibitors on silica gel thin-layer plate. Anal. Biochem. 1998, 258:149-150.
46. Di Scala C., Troadec J.D., Lelievre C., Garmy N., Fantini J., Chahinian H. Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer beta-amyloid peptide. J. Neurochem. 2013.
47. Schote U., Seelig J. Interaction of the neuronal marker dye FM1-43 with lipid membranes. Thermodynamics and lipid ordering. Biochim. Biophys. Acta 1998, 1415:135-146.
48. Jang H., Arce F.T., Ramachandran S., Capone R., Azimova R., Kagan B.L., Nussinov R., Lal R. Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer's disease and down syndrome. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6538-6543.
49. Puri A., Hug P., Munoz-Barroso I., Blumenthal R. Human erythrocyte glycolipids promote HIV-1 envelope glycoprotein-mediated fusion of CD4+ cells. Biochem. Biophys. Res. Commun. 1998, 242:219-225.
50. Hynds D.L., Takehana A., Inokuchi J., Snow D.M. l- and d-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) inhibit neurite outgrowth from SH-SY5Y cells. Neuroscience 2002, 114:731-744.
51. Ruan S., Lloyd K.O. Glycosylation pathways in the biosynthesis of gangliosides in melanoma and neuroblastoma cells: relative glycosyltransferase levels determine ganglioside patterns. Cancer Res. 1992, 52:5725-5731.
52. Vieira D.B., Thur K., Sultana S., Priestman D., van der Spoel A.C. Verification and refinement of cellular glycosphingolipid profiles using HPLC. Biochem. Cell Biol. 2015, 1-6.
53. Yamamoto N., Fukata Y., Fukata M., Yanagisawa K. GM1-ganglioside-induced Abeta assembly on synaptic membranes of cultured neurons. Biochim. Biophys. Acta 2007, 1768:1128-1137.
54. Mutoh T., Tokuda A., Miyadai T., Hamaguchi M., Fujiki N. Ganglioside GM1 binds to the Trk protein and regulates receptor function. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:5087-5091.
55. Fantini J., Yahi N., Garmy N. Cholesterol accelerates the binding of Alzheimer's beta-amyloid peptide to ganglioside GM1 through a universal hydrogen-bond-dependent sterol tuning of glycolipid conformation. Front. Physiol. 2013, 4:120.
56. Di Pasquale E., Fantini J., Chahinian H., Maresca M., Taieb N., Yahi N. Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides. J. Mol. Biol. 2010, 397:202-218.
57. Lashuel H.A., Hartley D., Petre B.M., Walz T., Lansbury P.T. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002, 418:291.
58. Park J., Jang M., Chang S. Deleterious effects of soluble amyloid-beta oligomers on multiple steps of synaptic vesicle trafficking. Neurobiol. Dis. 2013, 55:129-139.
59. Gaffield M.A., Betz W.J. Imaging synaptic vesicle exocytosis and endocytosis with FM dyes. Nat. Protoc. 2006, 1:2916-2921.
60. Goodall A.R., Danks K., Walker J.H., Ball S.G., Vaughan P.F. Occurrence of two types of secretory vesicles in the human neuroblastoma SH-SY5Y. J. Neurochem. 1997, 68:1542-1552.
61. Murphy N.P., Ball S.G., Vaughan P.F. Potassium- and carbachol-evoked release of [3H]noradrenaline from human neuroblastoma cells, SH-SY5Y. J. Neurochem. 1991, 56:1810-1815.
62. Butterfield S.M., Lashuel H.A. Amyloidogenic protein-membrane interactions: mechanistic insight from model systems. Angew. Chem. 2010, 49:5628-5654.
63. Lin H., Bhatia R., Lal R. Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J. 2001, 15:2433-2444.
64. Kayed R., Sokolov Y., Edmonds B., McIntire T.M., Milton S.C., Hall J.E., Glabe C.G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biolumin. Chemilumin. 2004, 279:46363-46366.
65. Yanagisawa K. Role of gangliosides in Alzheimer's disease. Biochim. Biophys. Acta 2007, 1768:1943-1951.
66. Fantini J., Garmy N., Yahi N. Prediction of glycolipid-binding domains from the amino acid sequence of lipid raft-associated proteins: application to HpaA, a protein involved in the adhesion of Helicobacter pylori to gastrointestinal cells. Biochemistry 2006, 45:10957-10962.
67. Mahfoud R., Garmy N., Maresca M., Yahi N., Puigserver A., Fantini J. Identification of a common sphingolipid-binding domain in Alzheimer, prion, and HIV-1 proteins. J. Biolumin. Chemilumin. 2002, 277:11292-11296.
68. Williamson M.P., Suzuki Y., Bourne N.T., Asakura T. Binding of amyloid beta-peptide to ganglioside micelles is dependent on histidine-13. Biochem. J. 2006, 397:483-490.
69. Diaz J.C., Linnehan J., Pollard H., Arispe N. Histidines 13 and 14 in the Abeta sequence are targets for inhibition of Alzheimer's disease abeta ion channel and cytotoxicity. Biol. Res. 2006, 39:447-460.
70. van Echten-Deckert G., Walter J. Sphingolipids: critical players in Alzheimer's disease. Prog. Lipid Res. 2012, 51:378-393.
71. Svennerholm L., Boström K., Jungbjer B., Olsson L. Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100years. J. Neurochem. 1994, 63:1802-1811.
72. Pena F., Ordaz B., Balleza-Tapia H., Bernal-Pedraza R., Marquez-Ramos A., Carmona-Aparicio L., Giordano M. Beta-amyloid protein (25-35) disrupts hippocampal network activity: role of Fyn-kinase. Hippocampus 2010, 20:78-96.
73. Oikawa N., Yamaguchi H., Ogino K., Taki T., Yuyama K., Yamamoto N., Shin R.W., Furukawa K., Yanagisawa K. Gangliosides determine the amyloid pathology of Alzheimer's disease. Neuroreport 2009, 20:1043-1046.
74. Mahadik S.P., Vilim F., Korenovsky A., Karpiak S.E. GM1 ganglioside protects nucleus basalis from excitotoxin damage: reduced cortical cholinergic losses and animal mortality. J. Neurosci. Res. 1988, 20:479-483.
75. Fantini J., Carlus D., Yahi N. The fusogenic tilted peptide (67-78) of alpha-synuclein is a cholesterol binding domain. Biochim. Biophys. Acta 2011, 1808:2343-2351.
76. Crowet J.M., Lins L., Dupiereux I., Elmoualija B., Lorin A., Charloteaux B., Stroobant V., Heinen E., Brasseur R. Tilted properties of the 67-78 fragment of alpha-synuclein are responsible for membrane destabilization and neurotoxicity. Proteins 2007, 68:936-947.
77. Mattson M.P., Cheng B., Davis D., Bryant K., Lieberburg I., Rydel R.E. Beta-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 1992, 12:376-389.
78. Fantini J., Barrantes F.J. Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function. Biochim. Biophys. Acta 2009, 1788:2345-2361.
79. Drin G., Rousselle C., Scherrmann J.M., Rees A.R., Temsamani J. Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors. AAPS PharmSci 2002, 4:E26.
80. Georgieva J.V., Brinkhuis R.P., Stojanov K., Weijers C.A., Zuilhof H., Rutjes F.P., Hoekstra D., van Hest J.C., Zuhorn I.S. Peptide-mediated blood-brain barrier transport of polymersomes. Angew. Chem. 2012, 51:8339-8342.
81. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
82. Glabe C.G. Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem. Sci. 2004, 29:542-547.